Memantine Tablet
Product Images NDC 60687-173

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Memantine (NDC 60687-173). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg Blister

This is information related to Memantine Hydrochloride tablets in various doses of 10mg and the text contains the drug name, Tablet, and some identifying numbers of the drug.*

FDA Label Image

10 mg Carton

This is a description of a drug named "Memantine Hydrochloride". Each package contains 60 tablets of size 6 x 10. The drug contains 10mg of Hiermantne hyorochiorde USP. The usual dosage information is provided with the package insert. The drug should be stored between 20° to 25°C. The package is distributed by American Geaih Pagaing.*

FDA Label Image

5 mg Blister

This is a list of different types of tablets of Memantine Hydrochloride at different dosages (5mg and smg) and under different names (Memanting, Wemarting, Wamanine, Wemaniine, Vemaripepcoctioride). It also includes batch and expiry information on some of the tablets.*

FDA Label Image

5 mg Carton

The text is a description of a medication called Memantine Hydrochloride in tablet form. The medication comes in a pack of 60 tablets and can only be obtained with a prescription. The pharmacist is advised to dispense the accompanying patient information sheet to each patient. The rest of the text is not readable.*

FDA Label Image

883dccf8 44b2 5f82 E053 2995a90a12dd

FDA Label Image

883dccf8 44b3 5f82 E053 2995a90a12dd

FDA Label Image

Memantine HCl Structural Formula (Image 01 01)

FDA Label Image

Figure 1: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 28 Weeks Of Treatment. (Image 02 01)

FDA Label Image

Figure 2: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Image 03 01)

FDA Label Image

Figure 3: Time Course Of The Change From Baseline In Sib Score For Patients Completing 28 Weeks Of Treatment. (Image 04 01)

FDA Label Image

Figure 4: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Image 05 01)

FDA Label Image

Figure 5: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 24 Weeks Of Treatment. (Image 06 01)

FDA Label Image

Figure 6: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Image 07 01)

FDA Label Image

Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Image 08 01)

FDA Label Image

Figure 8: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Image 09 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.